摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-异喹啉-1-基-3H-2-苯并呋喃-1-酮 | 24223-06-1

中文名称
3-异喹啉-1-基-3H-2-苯并呋喃-1-酮
中文别名
——
英文名称
1-(3-oxo-1,3-dihydroisobenzofuran-1-yl)isoquinoline
英文别名
3-(isoquinolin-1-yl)isobenzofuran-1(3H)-one;1-(1'-phthalidyl)-isoquinoline;3-isoquinolin-1-yl-3H-isobenzofuran-1-one;3--phthalid;3-(1-isoquinolinyl)-2-benzofuran-1(3H)-one;3-isoquinolin-1-yl-3H-2-benzofuran-1-one
3-异喹啉-1-基-3H-2-苯并呋喃-1-酮化学式
CAS
24223-06-1
化学式
C17H11NO2
mdl
——
分子量
261.28
InChiKey
DAAVHFJSZISNAH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    150-152 °C
  • 沸点:
    491.1±45.0 °C(Predicted)
  • 密度:
    1.322±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    39.2
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:b6045453aeca23067ff49d810dba6794
查看

反应信息

点击查看最新优质反应信息

文献信息

  • The Chemistry of Phthalide-3-carboxylic Acid. VII. Reaction With Isoquinoline Derivatives
    作者:C Donati、TV Hung、RH Prager
    DOI:10.1071/ch9900375
    日期:——

    Phthalide-3-carboxylic acid has been decarboxylated in the presence of isoquinoline, 1-chloroisoquinoline and isoquinoline N-oxides to give low yields of compounds resulting from alkylation of the isoquinoline heterocycle at C1 with a phthalidyl group. Attempted Barton decarboxylation-alkylation in the presence of isoquinolinium salts was unsuccessful.

    -3-羧酸异喹啉1-氯异喹啉异喹啉 N-氧化物存在下进行脱羧反应,得到的化合物产率很低,这些化合物是异喹啉杂环在 C1 处与酰基发生烷基化反应而产生的。尝试在异喹啉鎓盐存在下进行巴顿脱羧-烷基化反应并不成功。
  • [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA NASH, DE LA NAFLD ET DE L'OBÉSITÉ
    申请人:LIU JINGWEN
    公开号:WO2021067490A1
    公开(公告)日:2021-04-08
    The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound
    目前的技术涉及使用I、II、III、IV、V和/或VI式化合物治疗NASH、NAFLD和/或肥胖的方法。这些方法包括向患有非酒精性脂肪肝炎(NASH)、非酒精性脂肪肝病(NAFLD)和/或肥胖的受试者施用这种化合物的治疗有效剂量。
  • Central nervous system active compounds. VI. Reissert compounds as precursors of 1-(3-phthalidy1)isoquinolines
    作者:TV Hung、BA Mooney、RH Prager、AD Ward
    DOI:10.1071/ch9810151
    日期:——

    The reactions of isoquinoline and phthalazine Reissert compounds with phthalaldehydic acids and their derivatives have been investigated as a means of synthesizing 1-(3-phthalidyl)isoquinolines. Of a variety of conditions tried those involving phase transfer were found, in general, to be the most suitable. The products, which are analogues of the convulsant alkaloid bicuculline, showed weak central nervous system depressant activity.

    异喹啉酞嗪 异喹啉酞嗪 Reissert 化合物与邻苯二甲酸及其衍生物的反应,作为合成 1-(3-邻苯二甲酸基)异喹啉的方法进行了研究。 作为合成 1-(3-酰基)异喹啉的一种方法进行了研究。在尝试的各种条件中 发现涉及相转移的条件一般最合适。其 产品是惊厥碱的类似物 生物碱的类似物,显示出微弱的中枢神经系统抑制活性。 系统抑制活性。
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS
    申请人:Liu Haiyan
    公开号:US20090048246A1
    公开(公告)日:2009-02-19
    Compositions comprising extracts or isolated or purified compounds from plants of the genus Corydalis provide prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Corydalis compounds and their derivatives of natural and synthetic origins lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression and activate AMP-activated protein kinase. Specific stereoisomers of Corydalis compounds with lipid lowering activity include 14R-(+)-corypalmine, 14R,13S-(+)-corydaline, 14R-(+)-tetrahydropalmatin, (+)-corlumidin, d-(+)-bicuculline, and (+)-egenine.
    从黄堇属植物提取物或分离纯化的化合物构成的组合物可预防和治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征。黄堇化合物及其天然和合成来源的衍生物可降低总胆固醇、LDL-胆固醇甘油三酯,增加肝LDL受体表达并激活AMP激活蛋白激酶。具有降脂活性的黄堇化合物的特定立体异构体包括14R-(+)-可丹碱、14R,13S-(+)-可丹啉、14R-(+)-四氢棕榈碱、(+)-可鲁米丁、d-(+)-比库枯碱和(+)-艾根碱。
  • Central nervous system active compounds. VII. Phthalide synthesis by lithiation of alkoxyaromatics
    作者:TV Hung、BA Mooney、RH Prager、JM Tippett
    DOI:10.1071/ch9810383
    日期:——

    The lithiation of methoxy- and methylenedioxy-bemyl alcohols is described; subsequent reactions with ethyl chloroformate and carbon dioxide to form phthalides have been investigated, and are compared with metallation-carboxylation of alternative substrates. The preparation of phthalideisoquinoline analogues by this method proceeds only in low yields due to the acidity of the benzylic position in the benzylisoquinoline precursor.

    化 描述了甲氧基和亚甲二氧基-苯甲醇的石化作用。 随后与氯甲酸乙酯二氧化碳反应生成邻苯二甲酸酯。 和二氧化碳反应生成邻苯二甲酸盐的过程进行了研究。 与属化-羧化反应进行了比较。 其他底物的属化-羧化反应进行了比较。用这种方法制备邻苯二甲酸异喹啉类似物 类似物的产率很低,原因是苄基化合物中苄基位置的酸性 苄基异喹啉前体中苄基位置的酸性 前体中苄基位置的酸性。
查看更多

同类化合物

阿托喹啉 那可汀 那可丁N-氧化物 诺司卡品 盐酸盐 水合物 细果角茴香碱 紫堇明 盐酸那可丁一水合物 盐酸诺格考平 盐酸白毛莨碱 曲托喹啉 山缘草定碱 咖喏定 北美黄连碱 [S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞 [6S,(+)]-6-[(1S)-1,2,3,4-四氢-6,7-二甲氧基-2-甲基异喹啉-1-基]呋喃并[3,4-e]-1,3-苯并二氧戊环-8(6H)-酮 7-氨基-4,5,6-三乙氧基-3-(6,7,8-三甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基)-3H-2-苯并呋喃-1-酮 7-O-去甲基alpha-那可丁 6,7-二甲氧基-3-[(5R)-4-甲氧基-6-甲基-7,8-二氢-5H-[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-3H-2-苯并呋喃-1-酮 3-异喹啉-1-基-3H-2-苯并呋喃-1-酮 (3S)-6,7-二甲氧基-3-[(5S)-6-甲基-5,6,7,8-四氢[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-2-苯并呋喃-1(3H)-酮 (3S)-3-[(1R)-6,7-二羟基-8-甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基]-6,7-二甲氧基-3H-2-苯并呋喃-1-酮 (-)-荷苞牡丹碱甲溴化物 (-)-荷苞牡丹碱 (-)-荷包牡丹碱甲碘化物 (-)-荷包牡丹碱甲溴化物 (-)-荷包牡丹碱甲氯化物 (-)-紫堇明 (+)-荷苞牡丹碱甲氯化物 (+)-荷包牡丹碱 8-Isopentyl-narcotolin 8-<4-Chlor-benzyl>-narcotolin (R)-5-((R)-4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6,6-dimethyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolinium; iodide 8-Allylnarkotolin 8-p-Nitrobenzylnarkotolin 2-(thiazolidin-3-yl)ethyl (E)-6-[1,3-dihydro-4-(N-(trifluoroacetyl)-N-isopropyl)amino-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl]-4-methyl-4-hexenoate 2-[5-(4,5-Dimethoxy-3-oxo-1,3-dihydro-isobenzofuran-1-yl)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-4-yloxy]-N-(4-ethoxy-phenyl)-acetamide 8-Narcotolinessigsaeureethylester 2-[5-(4,5-Dimethoxy-3-oxo-1,3-dihydro-isobenzofuran-1-yl)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-4-yloxy]-N-(4-sulfamoyl-phenyl)-acetamide 6-(6',7'-diacetoxy-2'-methyl-1',2',3',4'-tetrahydroisoquinolin-1'-yl)furo<3,4-e>-1,3-benzodioxol-8(6H)-one hydrobromide 6,7-dimethoxy-3(7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)isobenzofuran-1(3H)-one 5-((R)-4,5-Dimethoxy-3-oxo-1,3-dihydro-isobenzofuran-1-yl)-6-methyl-7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinolin-6-ium (+/-)-erythro-1-<1'-(4',5'-dimethoxyphthalidyl)>-2-methyl-1,2,3,4-tetrahydroisoquinoline 6-(6',7'-dihydroxy-2'-methyl-1',2',3',4'-tetrahydroisoquinolin-1'-yl)furo<3,4-e>-1,3-benzodioxol-8(6H)-one hydrobromide 4-{2-[5-(4,5-Dimethoxy-3-oxo-1,3-dihydro-isobenzofuran-1-yl)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-4-yloxy]-acetylamino}-benzoic acid ethyl ester Corledin-acetat (-)-α-hydrastine; hydrochloride N-Aminonarcotiniumion 3d-β-Narcotin rac-2,3;10,11-bis-methanediyldioxy-16ξ-methyl-16ξ-oxy-rheadan-8-one (1R,5R)-8,9,18,19-tetramethoxy-3-oxa-13-azapentacyclo[11.8.0.01,5.06,11.016,21]henicosa-6,8,10,16,18,20-hexaene-4,12-dione